old
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A little over my head, (whom I kidding, way over my head), but here is some info on bio battery;
Patent ID: US7410709
Issue Date: August 12, 2008
Abstract:A bio-battery includes a biomolecular energy source, a first electrode and a second electrode. In some configurations, a bio-battery may also include a first cell containing the first electrode and the biomolecular energy source, and a second cell having a reducible substrate and the second electrode. The first cell can be in ionic communication with the second cell, for example by a proton exchange membrane. Various biomolecular energy sources can be used, including proton donor molecules or electrolytically oxidizable molecules. For example, the biomolecular energy source can be selected from the group consisting of Nicotinamide Adenine Dinucleotide (NADH), Nicotinamide Adenine Dinucleotide Phosphate (NADPH) and 5,10-Methylenetetrahydrofolate Reductase (FADH).
Tomikenow Reference Energy,
I did hear something about a new technology regarding batteries where current lead cell storage is replaced with bioengenered cells. I will research it and post.
A little over dramatic don't you think 'Khan', (I mean airone)
Seems kind of like those African ant swarms. On to the next penny stock.
It's my guess that Cowsert has the press releases pretty well staged til year end. (At least I hope he does).
can't really blame someone for selling at.11 if the bought at .01 a month ago. I'm just suprise that the volume was there to do it.
Where the heck was I when this was at $3.?? I long for the good ol days of .33. haha
HC, feed me some more corn on your earlier chicken thought.
I would like to retract a supposition I made regarding the last press release referencing 'positive test results'...
I questioned how there could be new test results without any scientist or lab technician currently working for the company.
Cowsert did state in his Update to Shareholders in Nov.'08 the following;
"As necessary we will recruit additional personnel, Board Members and Scientific advisors. However, it is also our goal to operate as a lean product development organization. We will achieve this by executing much of our work through contract research organizations thus giving CytoGenix maximum flexibility in the way we utilize our resources".
Based on these comments, the questions I raised by my comments had already been addressed by Cowsert, so my apologies.
I did find in rereading Cowsert's 11/08 Update to Shareholders, many of the activites currently publicized to be in line with plan as set forth within. For those wanting to reread I have added it at bottom of this much to long post.
November 24, 2008
Dear Shareholders, Colleagues and Friends:
As we come to the end of 2008, CytoGenix is poised to leave behind a very difficult period in its history and embark on a new stage of corporate development. I would like to take a few moments to describe several new developments that will facilitate this change as well as share with you my vision for the next stage of development for CytoGenix. First, I would like to introduce myself. I am Lex Cowsert, who as of November 14, 2008, have been appointed President, Chief Executive Officer and a Director to the Board of CytoGenix. I have over 19 years of experience in the biotech industry directing technology development, drug discovery and drug development programs in both public and private corporate settings. A more detailed description of my experience is posted on the CytoGenix web site.
CytoGenix is a company with many assets that will be the foundation upon which we can build value. However, CytoGenix is also a company facing many challenges. I believe that with new leadership and a new focus on product development, the CytoGenix management, staff, and scientific collaborators can work together to lead CytoGenix in a transition from a technology development and discovery company into a product development company. As a product development company, CytoGenix will deliver therapeutics, vaccines and services to the market and to strategic partners that will address unmet medical needs, generate revenue and build shareholder value.
The first step in this process will be to identify a product development candidate. CytoGenix has three promising candidates. Over the next few weeks we will be reviewing the preclinical data and market opportunities with the goal of designating one of these opportunities as a clinical development candidate. We plan to seek strong development and commercialization partners to generate revenue and accelerate the development of our product candidates and technology. Once we achieve certain financial milestones we will build drug development expertise in CytoGenix by recruiting additional new management with proven experience in drug development. As necessary we will recruit additional personnel, Board Members and Scientific advisors. However, it is also our goal to operate as a lean product development organization. We will achieve this by executing much of our work through contract research organizations thus giving CytoGenix maximum flexibility in the way we utilize our resources. In addition, we will develop plans to push our technologies and product candidates into additional markets. As we make progress towards these goals, I will update shareholders through public announcements that will also be posted on our Web site.
CytoGenix has been through some difficult times with financing being the primary obstacle. These difficulties resulted in several significant changes in management which have been described in various SEC filings and in the recent update from the Interim CEO posted on the CytoGenix web site. I would like to acknowledge my predecessors for their hard work and dedication to the development of the CytoGenix technologies and wish them well in their future endeavors. On the positive side, CytoGenix is now a company with a lean operating budget and multiple product candidates well positioned for internal development, partnering and out licensing with a focused management team to capitalize on these opportunities.
I would specifically like to thank Randy Moseley for stepping into the role of interim CEO and Chairman of the Board of Directors during a particularly difficult period. I am pleased to announce that Randy will remain in his roles as Principal Financial Officer and Chairman of the Board of Directors. I look forward to working closely with Randy as we build a strong financial foundation from which CytoGenix can execute it plans for generating revenue though product development and strategic partnerships. I would also like to thank board members, Cy Stein and John Rossi, for their fortitude, guidance and continued support through this recent transition period. Their understanding of the technology and our potential business opportunities has facilitated my recruitment and appointment to the CytoGenix team.
Finally, I would like to say I am very pleased to be joining the CytoGenix team at this pivotal stage of its corporate development. I am looking forward to working with the Company’s current management, its dedicated staff, and our team of world-renowned collaborators all in a focused effort to advance and commercialize our platform technologies and product candidates to build shareholder value.
Best Regards,
Lex M. Cowsert, President and Chief Executive Officer
Update From CEO
Financial Summary
Stock Quote
BigB #61870. I'm guilty of a tounge and cheek comment about the first movement after press release regarding R. Barry. If someone else predicted a high share price I am unaware of it.
If you would allow me to address this question, one of the main problems facing Cytogenix prior to the departure of all past mgmt and scientist was the delivery method it's technology. The methods studied at the end were injection, inhalation and electroporation as I recall, (and anyone please correct me if I'm not correct). Aldevron and Inovio were companies that Dr Chen had worked with and I beleive in both cases, electroporation was the delivery method tested. The last results of any test that I remember seeing, basically stated that Cytogenix synDNA vaccine delivered via electroporation was 'equal' or on par with the methodoly and approach that was employed at the time of the testing, (2007). Maybe it gotten better. For the Chicken's sake, I hope so. (That last thought was for you HC).
great character indeed!
Making Money now as in 'Revenue from selling something'? Do tell...
Airone, I can't help but picture the crazy Loatian character 'Kahn' from 'King of the Hill' when I read your idiotic posts.
Should be interesting what else they pull out of the 'closet of half truth and false innuendoes'. Roscoe, I'm afraid I'm a bit jaded......
Roscoe, Come on man, don't pay any attention to the man behind the curtain!!
May 2006 Link at bottom
HOUSTON -- CytoGenix, Inc. has entered into a research agreement with the Univ. of Texas Medical Branch Galveston for preclinical animal studies of synDNA(TM) H5N1 vaccine. Dr. Slobodan Paessler, scientific director of the Animal Biosafety Laboratory and the Galveston National Laboratory Advanced Veterinary Services Core will be supervising the research.
CytoGenix scientists have developed a synthetic DNA vaccine against a known strain of H5N1 as a test bed for efficacy and safety studies. In preparation for a possible Pandemic, the synDNA(TM) technology is designed to produce millions of doses of a DNA vaccine in a period of a few months.
The work will be performed in the Robert E. Shope, M.D., laboratory at the University of Texas Medical Branch, the only full-sized, maximum containment laboratory on a university campus in the United States and one of just four such BSL4 "space suit" laboratories currently operating in the U.S. The Galveston National Laboratory at UTMB is one of two National Biocontainment Laboratories now being constructed under grants awarded by the National Institute of Allergy and Infectious Diseases/National Institutes of Health. It will provide research space to develop therapies, vaccines and diagnostic tests for naturally occurring emerging diseases such as SARS and West Nile Encephalitis
as well as for viral and bacterial agents that might be employed by terrorists.
Dr. Yin Chen, CytoGenix vice president and chief scientific officer, states, "Dr. Paessler is an expert in infectious diseases animal models and has direct access to one of the few high containment laboratories in the country. One of the studies in this plan calls for a challenge with live virus to determine the degree of efficacy of the synDNA(TM) vaccine in conferring protection against H5N1 avian influenza."
http://www.thefreelibrary.com/CytoGenix+and+the+University+of+Texas+Medical+Branch+at+Galveston+...-a0145846161
Did they honestly think that they could throw out some old news in the midst of new announcements and have no one point out the fact that it is old news? Does the thought, "We may have been born at night but not last night", resonate with anyone beside roscoe and me? Come on....
One would have thought a public figure like Rick Barry wouldn't sell his reputation and dignity in this manner.
Let's just hope that the pumpers get caught with their shorts down on the race to the bottom.
Man I'd love to believe this is anything more than a scam but there is no evidence that it is, and to the contrary, it appears the powers that be are up to their old tricks. I will gladly eat my words if they can provide a test date after Chen's submitted results.
Who at Cytogenix is developing anything? Shouldn't we hear of a scientist, or at least a lab technician, being hired?
Sorry to be the stick in the mud folks but why were no test dates mentioned in the press release and are they re-releasing test results from Chens '07-'08 work. Yes much clinical coding looks impressive but when was this test completed??
HC/BigB
Based on the quote;
"We are excited to finally having a significant, strong Board of Directors with confidence and vision which will further enable our company the ability to see significant revenue within the coming months".
I'm curious as to your thoughts on what the source of revenue might be?
airone, you are like the football player who accidentally recovers a fumble then runs the wrong way with the ball celebrating all the way!! rigth now I'm patting you on the helmet and saying nice play. do you even read previous posts.
another 'good' possibly is that Stein, being in NYC, most likely has the ear of the investment community through some means. Sure would beat Skolnicks paid for ad interviews for exposure.
Look at tommorows ask
more accuratley 'tired' shoulders
New drug-resistant superbugs found in 3 states
http://news.yahoo.com/s/ap/20100913/ap_on_he_me/us_med_superbug_gene
Could be good timing??
I've been in this stock, (I'm almost ashamed to say), since early 2000's. More than the share price, the thing that will convince me something actually exists is whether Cowsert and the company deliver on something that he implies will happen. Cowsert mentioned revenue by end of year. That will be a nice measuring stick. Skolnick promised revenue and never delivered. Skolnick and Stein were/are peers. Skolnick wound up making decisions in the end that made me think he was either senile or very very corrupt.
For the record, I would like this co and the stock to take off but wannaB, you have to admit, of all the companies and all the stock, in all the land, foreign and domestic, this is certainly the one where you wouldn't want to count your chickens before the hatch!
Playground banter it is, Chen.
And Airone, so that I know the best method of aggrevation to use, do you ever actually present an educated thought, or are you more comfortable with playground banter.
No, I think I'll stay around awhile and aggravate you.
Prof. Cy Stein, MD, PhD
Prof. Dr. Cy Stein is Head of Medical Genitourinary Oncology and Professor of Medicine, Urology and Molecular Pharmacology at the Albert Einstein College of Medicine, New York. He also serves as an Attending Physician at the Montefiore Medical Center and is a Diplomate of nearly 20 years' standing of both the American Board of Internal Medicine and the American Board of Oncology.
Professor Stein is an internationally recognized innovator in the development of drugs based on antisense and RNA interference. In his distinguished career in research and treatment of cancers he has been involved for the past 15 years with leading preclinical and clinical trials of nucleic acid therapies. He is an editorial board member of Clinical Cancer Research, Molecular Cancer Therapeutics, Bioconjugate Chemistry and Cancer Gene Therapy, as well as Co-Editor of the journal Oligonucleotides (formerly Antisense and Nucleic Acid Drug Development) and has published over 150 papers in the field. Dr. Stein holds numerous patents related to experimental therapeutics with antisense and nucleic acids, and he is a world leader in this research area. He is currently on the scientific advisory boards of several companies including Genta and Atugen. Prof. Stein was a co-developer of Genta Inc's Genasense antisense drug for BCL-2-dependent breast cancer.
Prof Stein is a medical doctor and also has a PhD in chemistry. He is an oncologist and was trained at the New York Hospital/Cornell Medical Center and the National Institutes of Health. He was a professor at the College of Physicians and Surgeons at Columbia University for 13 years prior to taking up the chair at the Albert Einstein College. He is a pioneer in the research on anti-sense therapies against HIV/AIDS.
For my fellow stooges who would like to know more about Dr. Stein.
http://search.yahoo.com/search;_ylt=A0geu1v5QY5MALoAFZdXNyoA;_ylc=X1MDMjc2NjY3OQRfcgMyBGFvAzEEZnIDeWZwLXQtNzAxBGhvc3RwdmlkA0hGNWRSVW9HNzdtWFBjd3JURFlxZ0JBazJOZG51a3lPUWZrQUF5dU4Ebl9ncHMDMARuX3ZwcwMxMARvcmlnaW4Dc3JwBHF1ZXJ5A0RyLiBDeSBTdGVpbgRzYW8DMgR2dGVzdGlkA0g0NjU-?p=Dr.+Cy+Stein&fr2=sb-top&fr=yfp-t-701
Having Stein back in the mix is more important than a new cfo in my opinion. He seemed to be the authority on the application and commercialization of SSdna and synDNA back in the day when this board actually included science as part of the discussion. ISIS's patent block which prevented Simplvir from going forward may be finally addressed.
careful airone
I guarantee $50.00/share by christmas! OK .05/share by new year.
CytoGenix, Inc. Announces the Appointment of a New Chief Financial Officer